Total prostatectomy--a good option for residual prostate carcinoma after I-125 implantation of external radiotherapy

• Published in: Nederlands tijdschrift voor geneeskunde Vol. 143; no. 18; p. 945
• Main Authors: Horenblas, S, Efthymiou, K M, Meinhardt, W, Moonen, L M, van Tinteren, H
• Format: Journal Article
• Language: Dutch
• Published: Netherlands 01.05.1999
• Subjects: Aged; Humans; Iodine Radioisotopes - radiation effects; Male; Middle Aged; Neoplasm, Residual; Prostatectomy; Prostatic Neoplasms - mortality; Prostatic Neoplasms - radiotherapy; Prostatic Neoplasms - surgery; Radiotherapy - methods; Recurrence; Retrospective Studies; Salvage Therapy; Survival Rate
• ISSN: 0028-2162

To evaluate the results of salvage prostatectomy after previous radiation therapy for locally confined prostate cancer. Retrospective. Data were collected from the records of all patients with prostate cancer who underwent salvage prostatectomy after I-125 implantation or external radiation therapy in the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands, 1991-1997. Indications for surgery were: locally confined histologically proven residual cancer, good life expectancy, fit for surgery. Standard preoperative workup was done together with a tumour marker measurement, transrectal ultrasound with biopsy of the prostate and a bonescan. Per- an postoperative complications, pathology result and postoperative PSA were assessed. Progression free survival, overall survival and cancer specific survival were calculated according to the Kaplan-Meier method. 10 patients with a mean age of 67.2 years (range: 57-79) and a median follow up of 78 months (range: 0-89) underwent a total prostatectomy after I-125 implantation (7 patients) or external radiation therapy (3 patients). One patient died after the operation from acute tubular necrosis. One patient developed an internal hernia, requiring surgery. Four patients needed pads during the daytime for stress incontinence for urine. The 5-year progression free survival was 72% (95% confidence interval (95% CI): 44-100), the overall survival was 90% (95% CI: 73-100) and the cancer specific survival was 90% (95% CI: 73-100). No local recurrences were detected. The local control and the 5-year survival were good in this selected patient group.